+A -A

Tabela:
Comparative View:

2017 Create chart
Net sales revenues 3,990,866
Change in Fair Value of Biological Assets 214,933
Cost of Goods Sold -2,540,874
Depreciation / Amortization / exhaustion -398,038
Exhaustion of biological assets -123,118
Gross Profit 1,143,769
Selling Expenses -638,521
General and Administrative Expenses -143,308
Management Compensation -15,612
Other Operating Compensation 75,013
Equity income from subsidiaries 0
Operating Profit before Financial Income and Equity 421,341
Financial Income 163,031
Financial Expenses -369,144
Income Before Income Tax and Social Contribution 215,228
Income and social contribution taxes - current -58,244
Income Tax and Social Contribution - Deferred 28,031
Effect profit from discontinued operation 0
Net Income 185,015
Recurring Net Income 180,668
Recurring EBITDA 760,010
EBITDA Margin 19.0 %

* Because of the date of the merger between Duratex and Satipel, 31.08.09, include data only from the "old" Duratex

**from 1Q 12 the data does not include discontinued operation, Deca Piazza